The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Metastatic Prostate Cancer Clinical Trial

Official title:

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04876651
• Other study ID #: 177Lu-TLX591-002
• Status: Recruiting
• Phase: Phase 3
• Start date: August 29, 2023
• Est. completion date: December 1, 2028

Study information

• Verified date: May 2024
• Source: Telix Pharmaceuticals (Innovations) Pty Limited
• Contact: Brenda Cerqueira, M.Sc
• Phone: +61 83180090
• Email: brenda.cerqueira[@]telixpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multinational, multicenter, prospective, randomized, controlled, open label Phase 3 study is designed to investigate and confirm the benefits and risks associated with the PSMA-targeted antibody, 177Lu DOTA rosopatamab administered together with Standard of Care (SoC), as compared to the best SoC alone. The phase 3 will be conducted in patients with metastatic castration-resistant PC (mCRPC) that expresses PSMA and has progressed despite prior treatment with a novel androgen axis drug (NAAD).

Description:

This multinational, multicenter, prospective, randomized, controlled, open label Phase 3 study is designed to investigate and confirm the benefits and risks associated with 177Lu DOTA rosopatamab administered together with SoC, as compared to the best SoC alone, in patients with PSMA-positive, metastatic castration-resistant PC (mCRPC) that has progressed despite prior treatment with a novel androgen axis drug (NAAD).

PSMA positivity will be defined by gallium-68 labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography/computerized tomography (PET/CT) as at least one site of metastatic disease with intensity significantly greater than normal liver (i.e., standardized uptake value [SUV] max at least 1.5 times SUV of normal liver.

Approximately 392 eligible adult male will be part of this study. 387 patients will be randomized to one of two groups in a 2:1 ratio to receive one of the treatments below. 5 participants in New Zealand will be enrolled into a sub-study.

• Group A: Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC

• Group B: Best SoC.

In parallel to this, 5 participants in New Zealand site, will be enrolled into a sub-study to investigate the biodistribution, pharmacokinetics and dosimetry of 177Lu-DOTA-TLX591(m17). Participants will receive two doses of 177Lu-DOTA-TLX591(m17), 14 days apart.

Screening procedures will take up to 28 days prior to enrollment and randomization. Only patients with PSMA-positive metastatic PC and meeting all other inclusion/exclusion criteria were randomized in a 2:1 ratio to Group A or B OR allocated to Sub-study in New Zealand.

Participants in Group A or B will participate in the study for up to 5 years. During this period the participants will undergo imaging procedures approximately every 6-8 weeks until progression.

Participants in the sub-study will participate in the study up to 23 days. During this period participants will receive two doses of 177Lu-DOTA-TLX591(m17), 14 days apart, and undergo SPECT/CT imaging and blood collection for Pharmacokinetics at days 1,2,5,8, 13 and 15.

For all patients, the best SoC will be determined by the Principal Investigator (PI) and the medication will be provided until progression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 392
• Est. completion date: December 1, 2028
• Est. primary completion date: November 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be a male, at least 18 years old, with metastatic adenocarcinoma of the prostate defined by histological / pathological confirmation of PC.

2. Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of =6 months.

3. Have metastatic disease (=1 metastatic lesions present on baseline CT, MRI, or bone scan imaging).

4. Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing hormone [LHRH]) and must have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L).

5. In the mCRPC setting, must have received a minimum of 12 weeks of prior therapy with a NAAD, either enzalutamide or abiraterone plus prednisone.

6. Should have received one line of prior taxane therapy or have refused or be ineligible for taxanes

7. Have a disease that is progressing at study entry, despite a castrate testosterone level (<50 ng/dL or <1.7 nmol/L), by the demonstration of at least one of the following:

1. Rising PSA values done in sequence at least 1 week apart and with a minimal starting value of 2.0 ng/mL.

2. Progressive disease or new lesion(s) in the viscera or lymph nodes as per RECIST1.1 or in bone as per Prostate Cancer Working Group 3 [PCWG3; Scher et al., 2016]). Any ambiguous results are to be confirmed by other imaging modality (e.g., CT or MRI scan).

8. Have disease that is PSMA positive, as demonstrated by a 68Ga-PSMA11 PET/CT scan and confirmed as eligible by the Sponsor's central reader (patient must have at least one site of metastatic disease with SUVmax =1.5 times the SUV of normal liver). If the disease meets the criteria for PSMA positivity, but there is one or more soft tissue lesion of = 2 cm that is not PSMA positive, then the patient is to be excluded on the grounds that there is substantial disease which might not respond to the therapy.

9. Must have recovered to = Grade 2 from all clinically significant toxicities related to prior therapies (i.e., surgery, local radiotherapy, NAAD, chemotherapy, etc.).

10. Can be receiving a bisphosphonate or denosumab regimen provided that the patient has been receiving and tolerating this treatment for =30 days prior to randomization.

11. Have adequate organ function at Screening:

a. Bone marrow: i. Platelets =150×109/L. ii. Absolute neutrophil count >1.5×109/L. iii. Hemoglobin =10g/dL (no red blood cell transfusion in the previous 4 weeks).

b. Liver function: i. Total bilirubin < 1.5×the upper limit of normal (ULN). For patients with known Gilbert's Syndrome <3×ULN is permitted. ii. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <3×ULN OR <5×ULN for patients with liver metastases. c. Renal function: i. Serum/plasma creatinine <1.5×ULN or creatinine clearance =50 mL/min determined using the Cockcroft & Gault formula.

12. Have the capacity to understand the study and be able and willing to comply with all protocol requirements.

13. Patients must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution in order to protect their contacts and the general public, especially if a female partner of the patient is or could be pregnant.

14. Must agree to practice adequate precautions to prevent pregnancy in a partner and to avoid potential problems associated with radiation exposure to the unborn child (Refer to Clinical Trials Facilitation Group, 2020: Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, CTFG, 2020).

Exclusion Criteria:

1. Are unable to understand or are unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the Investigator.

2. Have PC associated with pathological findings consistent with small cell or any histology other than adenocarcinoma of the prostate. If there are minor elements of neuroendocrine histology, this is acceptable.

3. Uncontrolled pain.

4. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease-free for more than 3 years are eligible, as are patients with adequately treated non-melanoma skin cancer, and superficial bladder cancer.

5. Are at increased risk of hemorrhage or bleeding, or with a recent history of a thrombolytic event (e.g., deep vein thrombosis [DVT]/ pulmonary embolism [PE]) and have been administered long-term anti-coagulant or anti-platelet agents.

6. Have received prior treatment with monoclonal antibody (mAb) J591 or HuJ591 or any other PSMA targeted therapy.

7. Have known allergies, hypersensitivity, or intolerance to the investigational drug or its excipients.

8. Have received prior systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy, or biological therapy) and/or radiation therapy within 4 weeks of randomization OR if any significant AEs have not resolved to National Cancer Institute (NCI) AE Criteria =2; OR are receiving other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy.

9. Have received prior treatment with radioisotopes, including but not limited to:

89Strontium, 153Samarium, 186Rhenium, 188Rhenium, 223Radium, or hemi-body irradiation within 6 months prior to randomization.

10. Have received other investigational therapy within 4 weeks of randomization.

11. Have known brain metastases or hepatic metastases.

12. Have a history of seizure and/or stroke within past 6 months.

13. Have clinical or radiologic findings indicative of impending cord compression or experience symptomatic cord compression.

14. Have a serious active or sub-clinical infection or angina pectoris (New York Heart Association [NYHA] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, which might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment, particularly with enzalutamide.

15. Have received treatment with any PARP inhibitors (i.e., Olaparib) or with any platinum based anti-neoplastic drugs.

16. Have a known alteration in breast cancer genes (BRCA) BRCA1, BRCA2, or Ataxia Telangiectasia Mutated Gene (ATM) gene and are eligible to receive Olaparib therapy according to their institution's SoC

Related Conditions & MeSH terms

• Metastatic Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• 177Lu-DOTA-rosopatamb
Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC

Drug:
• Standard of Care
enzalutamide or abiraterone [+ prednisone/prednisolone)] or docetaxel

Locations

Country	Name	City	State
Australia	Monash Health	Clayton	Victoria
Australia	Austin Health	Melbourne	Victoria
Australia	'GenesisCare Murdoch'	Murdoch	Western Australia
Australia	Westmead Hospital	Westmead	New South Wales
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
New Zealand	Auckland City Hospital	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Telix Pharmaceuticals (Innovations) Pty Ltd

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of radiographic progression-free survival (rPFS)	Radiographic progression-free survival (rPFS) defined as the time from randomization to disease progression confirmed by central independent radiology review according to RECIST 1.1 (for soft tissue disease) and/or PCWG3 criteria (for bone disease), or death (whichever occurs first).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Overall survival	Overall survival (OS), determined from randomization, until death from any cause	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Tumour objective response rate (ORR)	Tumor response in terms of objective response rate (ORR) (malignant soft tissue response and overall radiological response [malignant soft tissue response by RECIST 1.1 and overall radiological response by RECIST 1.1 and PCWG3]).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Time to a first Symptomatic Skeletal Event (SSE)	Time to a first SSE, defined as the use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological fracture (vertebral or non-vertebral), or occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Progression-free survival	PFS defined as the time from randomization to disease progression confirmed by radiology, clinical or PSA progression, or death (whichever occurs first).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Assessment of AEs graded by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, vital signs (systolic and diastolic blood pressures, respiratory rate, pulse rate, and body temperature), ECGs, and evaluation of laboratory parameters (biochemistry, hematology, coagulation, and urinalysis).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Adverse events of special interest (AESI)	Assessment of any Grade 4 hematological abnormalities and bleeding events and Symptomatic skeletal events (SSE), defined as the use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathological fracture (vertebral or non-vertebral), or occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention.	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Health-related quality of life by ECOG	Quality of Life is to be evaluated using the Eastern Cooperative Oncology Group (ECOG) Performance Scale- From 0 (fully active) to 5 (dead).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Health-related quality of life by FACT-P	The Functional Assessment of Cancer Therapy-Prostate (FACT-P) evaluates the physical well-being, social/family well-being, emotional well-being and functional well-being), the results range from "not at all" to "Very much"	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Health-related quality of life by BPI-SF	The Brief Pain Inventory - Short Form (BPI-SF) where the results vary from 1-4 (mild pain), 5-6 (Moderate pain) and 7-10 (severe pain)	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Health-related quality of life by EQ-5D-5L	The EQ-5D-5L where the results vary from 1 (no problems) to 5 (extreme problems/unable to do)	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Health-related quality of life by EORTC/QQ-C30	The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) questionnaire - result is calculated from the mean of 13 of the 15 QLQ-C30 scales (Physical Functioning+ Role Functioning+ Social Functioning+ Emotional Functioning+ Cognitive Functioning+ Fatigue+ Pain+ Nausea_Vomiting+ Dyspnoea+ Sleeping Disturbances+ Appetite Loss+ Constipation+ Diarrhoea) ranging from "not at all" to "Very much"	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Assessment of changes in prostate specific antigen (PSA)	Percentage change from baseline in PSA level, PSA response, and PSA response duration	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Time to radiographic soft tissue progression (TTSTP)	Time to radiographic soft tissue progression (TTSTP) defined as time from randomization to radiographic soft tissue progression according to RECIST 1.1 (for soft tissue disease).	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Biochemical response as indicated by PSA levels, lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) levels	Percentage change from baseline in PSA level, PSA response, and PSA response duration and percentage change from baseline in blood LDH/ALP levels.	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Development of anti-drug antibodies (ADA) to 177Lu-DOTA-TLX591	A blood test to check if antibodies are formed against the study drug, and how much of the antibodies is formed and if it is enough to neutralize the study drug. ADA can reduce or neutralise the drug's effectiveness as the body tries to neutralize the drug.	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Titer of anti-drug antibodies (ADA) to 177Lu-DOTA-TLX591	The concentration (ug/mL) of anti-drug antibodies (ADA) to 177Lu-DOTA-TLX591	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Duration of positiveness in the development of anti-drug antibodies (ADA) to 177Lu-DOTA-TLX591	In case of DA positiveness, this will analise how long the ADA positiveness is measured in the study samples.	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Neutralizing anti-drug antibodies (NAb) to 177Lu-DOTA-TLX591	How many study samples have been positive (rate) for neutralizing anti-drug antibodies (NAb) to 177Lu-DOTA-TLX591. NAb can neutralize the biological drugs and decrease the drug's efficacy and increase its clearance, resulting in patient secondary unresponsiveness.	Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab
Secondary	To determine whole body biodistribution (BD) of administered activity 177Lu-DOTATLX591(m17)	Evaluate whole body and organs imagining positivity for administered 177Lu-DOTATLX591 (m17)	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab
Secondary	To determine organ radiation dosimetry of tracer levels of administered activity 177Lu-DOTATLX591(m17)	Evaluate organs absorbed radiation doses of administered 177Lu-DOTATLX591 in PSMA expressing tumours as determined by suitable tumour-to-heathy tissue ratios and residence times.	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab
Secondary	To determine pharmacokinetics (PK) of administered activity 177Lu-DOTATLX591	Measure whole blood radioactive concentration at each timepoint to determine the radiation PK curve.	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Demonstrate comparability of whole body biodistribution dosimetry of the 177Lu-DOTA-TLX591	Qualitative comparison measured in SUV (Standardized Uptake Value) of whole-body biodistribution between 177Lu-DOTA-TLX591 from ProstACT-SELECT participants (NCT04786847) and this study's participants	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Demonstrate comparability of organ uptake dosimetry of the 177Lu-DOTA-TLX591	Qualitative comparison measured in SUV (Standardized Uptake Value) of organ uptake between 177Lu-DOTA-TLX591 from ProstACT-SELECT participants (NCT04786847) and this study's participants	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab
Secondary	Demonstrate organ radiation dosimetry comparability of the 177Lu-DOTA-TLX591	Qualitative comparison of organ dosimetry from ProstACT-SELECT participants (NCT04786847) and 177Lu-DOTA-TLX591 (m17 allotype)	Day 1 to day 23 after two administrations of 177Lu-DOTA-rosopatamab